Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Nektar Therapeutics (NKTR) könnte durch solides Quartalsergebnis die Abwärtsbewegung der letzten Monate beenden Nektar Therapeutics (NKTR) meldete meldete gestern nachbörslich einen Quartalsverlust in Höhe von -0,56 USD pro Aktie, was die Analystenkonsensschätzung von -0,63 USD um 11,11 Prozent übertraf. Beim Umsatz konnte man mit 27,762 Mio. USD die Analystenkonsensschätzung in Höhe von...
Nektar Therapeutics stock falls after announcing public offering
The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday,...
Nektar Therapeutics stock soars after atopic dermatitis drug hits key targets
Nektar Therapeutics stock soars on upcoming atopic dermatitis data
